These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31219877)

  • 1. Predictors of heart failure development in type 2 diabetes: a practical approach.
    Verma S; Sharma A; Kanumilli N; Butler J
    Curr Opin Cardiol; 2019 Sep; 34(5):578-583. PubMed ID: 31219877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice.
    Dogar ME; Azeem B; Asim R
    Int J Cardiol; 2023 Nov; 390():131255. PubMed ID: 37562752
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of diabetic cardiomyopathy in patients with type 2 diabetes in a large academic medical center.
    Swiatkiewicz I; Patel NT; Villarreal-Gonzalez M; Taub PR
    BMC Med; 2024 May; 22(1):195. PubMed ID: 38745169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rethinking the Impact and Management of Diabetes in Heart Failure Patients.
    Schütt K
    Curr Heart Fail Rep; 2024 Feb; 21(1):53-60. PubMed ID: 38047986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comorbidities in Heart Failure: Expect and Embrace the Complexity.
    Ambardekar AV; Thielen SC
    JACC Heart Fail; 2023 Nov; 11(11):1504-1506. PubMed ID: 37565975
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to comment on "Subclinical myocardial injury increases the risk of heart failure in patients with and without type 2 diabetes post-acute coronary syndrome".
    Jong CB; Lu TS; Chen JW
    Int J Cardiol; 2024 Jul; 407():132031. PubMed ID: 38609054
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-World Evidence Supports Higher Prevalence of Heart Failure Among Persons With Type 1 and Type 2 Diabetes Compared With the General Population.
    Garrett V; Gombar S; Huang J; Yeung AM; Klonoff DC
    J Diabetes Sci Technol; 2023 May; 17(3):864-865. PubMed ID: 36824057
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved Treatment For Diabetes Type 2 Associated Heart Failure.
    Alamgir MU
    J Pak Med Assoc; 2023 Sep; 73(9):1934-1935. PubMed ID: 37817724
    [No Abstract]   [Full Text] [Related]  

  • 9. Heart Failure Risk Under Covers: Sleeping With the Enemy.
    Gupta K; Sauer AJ; VAN Spall HGC
    J Card Fail; 2024 Mar; 30(3):449-451. PubMed ID: 38000733
    [No Abstract]   [Full Text] [Related]  

  • 10. SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
    Santos-Ferreira D; Gonçalves-Teixeira P; Fontes-Carvalho R
    Cardiology; 2020; 145(5):311-320. PubMed ID: 31865310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects.
    Lam CSP; Chandramouli C; Ahooja V; Verma S
    J Am Heart Assoc; 2019 Oct; 8(20):e013389. PubMed ID: 31607208
    [No Abstract]   [Full Text] [Related]  

  • 12. What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
    Khan MS; Vaduganathan M
    Curr Diab Rep; 2020 Oct; 20(11):63. PubMed ID: 33040170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments.
    Iwakura K
    J Echocardiogr; 2019 Dec; 17(4):177-186. PubMed ID: 31617144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.
    Genuardi MV; Mather PJ
    Ther Adv Cardiovasc Dis; 2021; 15():17539447211002678. PubMed ID: 33779401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of the Proposed Mechanistic Actions of Sodium Glucose Cotransporter-2 Inhibitors in the Treatment of Heart Failure.
    Nightingale B
    Cardiol Res; 2021 Apr; 12(2):60-66. PubMed ID: 33738008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review.
    Taylor OM; Lam C
    Curr Ther Res Clin Exp; 2020; 93():100596. PubMed ID: 32817765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
    Perry RJ; Shulman GI
    J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.
    Lopaschuk GD; Verma S
    JACC Basic Transl Sci; 2020 Jun; 5(6):632-644. PubMed ID: 32613148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.